Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11908378 | 0.84 | CYP19A1 (0.46) | CYP19A1TSHRNPSR1EPHX2CYP17A1 | |
| SCHEMBL7436688 | 0.77 | CYP19A1 (0.35) | CYP19A1TSHRNPSR1EPHX2CYP17A1 | |
| SCHEMBL11907438 | 0.77 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL950698 | 0.77 | CYP19A1 (0.34) | CYP19A1 | |
| SCHEMBL952639 | 0.75 | TRPA1 (0.33) | CYP19A1 | |
| SCHEMBL950229 | 0.75 | EPHX2 (0.31) | CYP19A1EPHX2 | |
| SCHEMBL2820778 | 0.75 | CYP19A1 (0.34) | CYP19A1TSHRNPSR1EPHX2CYP17A1 | |
| SCHEMBL4858292 | 0.75 | OPRM1 (0.36) | CYP19A1TSHRNPSR1EPHX2CYP17A1 | |
| SCHEMBL14480228 | 0.72 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL2963861 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0405391-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1991-01-02 | — | — | EP | claimed |
| EP-0660840-B1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| US-5550119-A | ENDOTHELIN-CONVERTING ENZYM INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-08-27 | — | — | US | disclosed |
| US-5426103-A | Endopeptidase inhibitors; condensing macrocylic compound with a thioic acid or salt therof; possible esterification, salt formation, deslating, deprotecting, deesterifying of function-al groups | CIBA-GEIGY CORPORATION (US) | 1995-06-20 | — | — | US | disclosed |
| US-5354892-A | Treating cardiovascular disorders; endopeptidase inhibitors; diuretics | CIBA-GEIGY CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| US-5250522-A | Neutral endopeptidase inhibitors; cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
| US-5244889-A | Treatment of cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0555175-A1 | Biaryl substituted 4-amino-butyric acid amides | CIBA-GEIGY AG (CH) | 1993-08-11 | — | — | EP | disclosed |
| US-5217996-A | Endopeptidase inhibitors | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0544620-A1 | Macrocyclic lactams as inhibitors of atrial natriuretic factors (ANF)-degrading neutral endopeptidase (NEP) | CIBA-GEIGY AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| US-5153214-A | Treating cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0405391-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1991-01-02 | — | — | EP | disclosed |